Core Points - Lavoro Limited received a notice of non-compliance from Nasdaq due to delayed filing of its Form 20-F for the year ended June 30, 2025 [1][2] - The company is required to submit a plan by November 28, 2025, to regain compliance with Nasdaq's listing rules [3][4] - The delay in filing is attributed to complexities associated with the EJ Plan announced in June 2025 [2] Company Overview - Lavoro is Brazil's largest agricultural inputs retailer and a leading producer of agricultural biological products [5] - The company operates across Latin America, including Brazil, Colombia, Uruguay, and Ecuador, and empowers small and medium-sized farmers with emerging agricultural technologies [5]

ARLINGTON, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three months and full fiscal year ended September 30, 2025. Fiscal Year 2025 Financial Highlights Revenue of $2.3 billion for fiscal year 2025 and $1.0 billion for the fourth quarter, compared to $2.7 billion and $1.2 billion from the same ...

Core Viewpoint - Oxford Industries, Inc. plans to release its third quarter fiscal 2025 financial results on December 10, 2025, after market close, followed by a conference call to discuss the results [1]. Company Information - Oxford Industries is a leader in the apparel industry, owning and marketing several distinctive brands including Tommy Bahama®, Lilly Pulitzer®, Johnny Was®, Southern Tide®, The Beaufort Bonnet Company®, Duck Head®, and Jack Rogers® [3]. - The company's stock has been traded on the New York Stock Exchange since 1964 under the symbol OXM [3]. Conference Call Details - The conference call will be hosted by Thomas C. Chubb III, Chairman, CEO, and President, and K. Scott Grassmyer, Executive Vice President, CFO, and COO, starting at 4:30 p.m. ET [1]. - A live webcast of the conference call will be available on the company's website, with a replay accessible until December 24, 2025 [2].

Core Insights - Rani Therapeutics is participating in the Evercore Healthcare Conference on December 3, 2025, with CEO Talat Imran and CFO Svai Sanford presenting [1] - The company focuses on oral delivery of biologics and drugs, aiming to replace traditional injection methods with its proprietary RaniPill capsule technology [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to advancing technologies for orally administered biologics and drugs [2] - The RaniPill capsule is a novel, proprietary, and patented platform technology designed to facilitate oral dosing instead of subcutaneous or intravenous methods [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill capsule technology [2]

Core Insights - ORIC Pharmaceuticals, Inc. is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [3] - The company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 11:15 a.m. ET [1] - A webcast of the fireside chat will be available on the company's investor website, with a replay accessible for 90 days post-event [2] Company Overview - ORIC Pharmaceuticals is dedicated to improving patients' lives by overcoming resistance in cancer [3] - The company's clinical stage product candidates include ORIC-944, an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2) for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor for various genetically defined cancers [3] - ORIC has offices located in South San Francisco and San Diego, California [3]

Core Insights - Zoom Communications, Inc. reported a total revenue of $1,229.8 million for the third fiscal quarter, reflecting a year-over-year increase of 4.4% as reported and 4.2% in constant currency [4][5] - The company emphasized its commitment to an AI-first platform, highlighting the growth in adoption of its AI Companion 3.0 and Custom AI Companion, contributing to strong customer experience metrics [2][4] - The financial results indicate significant profitability, with GAAP EPS increasing by 204.5% year-over-year to $2.01, and non-GAAP EPS rising by 10.1% to $1.52 [4][5] Financial Performance - Total revenue for Q3 was $1,229.8 million, with Enterprise revenue at $741.4 million, up 6.1% year-over-year, and Online revenue at $488.4 million, up 2.0% [4][5] - GAAP operating margin stood at 25.2%, while non-GAAP operating margin was 41.2% [5][36] - Operating cash flow reached $629.3 million, marking a 30.2% increase year-over-year, with a cash flow margin of 51.2% and free cash flow margin of 50.0% [4][5][37] Shareholder Returns - The company repurchased approximately 5.1 million shares in Q3, totaling 32.5 million shares repurchased under the current plan [4][9] - The Board of Directors authorized an additional $1.0 billion for stock repurchase, increasing the total authorization to $1.310 billion [9][11] Customer Metrics - The number of customers contributing over $100,000 in trailing 12 months revenue increased by 9.2% year-over-year, totaling 4,363 customers [4][13] - The trailing 12-month net dollar expansion rate for Enterprise customers was reported at 98% [13] - Online average monthly churn remained stable at 2.7% year-over-year, with 74.4% of total Online MRR from customers with a continual term of service of at least 16 months [13] Financial Outlook - For Q4 FY 2026, total revenue is expected to be between $1.230 billion and $1.235 billion, with non-GAAP income from operations projected between $477.0 million and $482.0 million [13] - The full fiscal year 2026 revenue guidance is between $4.852 billion and $4.857 billion, with non-GAAP income from operations expected between $1.955 billion and $1.960 billion [13]

Core Insights - Alico, Inc. has successfully transitioned from a traditional citrus producer to a diversified land company, with a strategic focus on land development and agricultural operations [2][3][25] - The company reported a net loss of $147.3 million for the fiscal year ended September 30, 2025, primarily due to accelerated depreciation and impairments, despite achieving an Adjusted EBITDA of $22.5 million [3][4][6] - Alico's land sales reached $23.8 million, exceeding guidance, and the company ended the fiscal year with $38.1 million in cash, providing financial flexibility through fiscal year 2027 [3][4][19] Financial Performance - For the fiscal year ended September 30, 2025, Alico's total revenue was $44.1 million, a decrease of 5.5% from $46.6 million in 2024 [4][35] - The net loss attributable to Alico common stockholders was $147.3 million, compared to a net income of $7.0 million in the previous year, reflecting a significant decline [4][35] - Adjusted EBITDA for the fiscal year was $22.5 million, down from $29.7 million in 2024, indicating challenges in operational performance [6][35] Citrus Operations - Alico harvested 2.3 million boxes of citrus fruit in fiscal year 2025, a decrease of 25.9% from the previous year, primarily due to Hurricane Milton's impact [9][35] - The average realized price per pound solids increased from $2.81 to $3.66, benefiting from favorable pricing contracts [9][35] Land Management and Development - Approximately 25% of Alico's land holdings are earmarked for strategic development, while 75% remain in diversified agriculture, creating a balanced platform for growth [2][3] - The Corkscrew Grove Villages project is a significant development initiative, expected to provide economic benefits and enhance public infrastructure in Collier County [16][17] - Alico has established the Corkscrew Grove Stewardship District to finance infrastructure and manage natural areas, supporting the Corkscrew Grove Villages project [18][19] Conservation Efforts - Alico has a long-standing commitment to conservation, having transferred lands to various protected areas and plans to place an additional 6,000 acres into permanent conservation as part of its development projects [21][22][23] - The company sold over 17,000 acres of land to the Florida Department of Environmental Protection as part of the Florida Forever program, enhancing connectivity between conservation lands [22][23] Balance Sheet and Liquidity - As of September 30, 2025, Alico reported cash and cash equivalents of $38.1 million and a net debt of $47.4 million, indicating a strong liquidity position [4][19] - The company's current ratio was 9.56 to 1.00, reflecting robust working capital management [19][20]

Core Insights - Praxis Precision Medicines is set to present new preclinical and clinical data on its precision epilepsy pipeline at the American Epilepsy Society Annual Meeting from December 5-9, 2025, in Atlanta, Georgia [1][2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly those related to neuronal excitation-inhibition imbalance [13] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [13] Pipeline and Research Highlights - The company will showcase its precision epilepsy programs through multiple presentations, including late-breaking presentations and a dedicated scientific exhibit at Booth 217 [3][4] - Key programs being highlighted include vormatrigine, relutrigine, and elsunersen, with specific presentations scheduled for December 6 and 8 [4][5][6] - Vormatrigine is a next-generation treatment for focal onset seizures and generalized epilepsy, showing superior selectivity and potency in preclinical studies [10] - Relutrigine is in development for developmental and epileptic encephalopathies, demonstrating robust seizure control in preclinical models and well-tolerated results in Phase 1 studies [11] - Elsunersen targets SCN2A gene expression to treat early-onset seizures, showing significant reductions in seizures and improved outcomes in preclinical models [12] Event Participation - Praxis will engage with attendees at the AES meeting, inviting them to learn more about the company's research and commitment to advancing epilepsy therapies [3][4] - The scientific exhibit will feature all conference posters, with team members available for discussions on clinical updates and progress [4]

Core Points - Hingham Institution for Savings has declared a regular quarterly dividend of $0.63 per share, payable on January 14, 2026, to stockholders of record as of January 5, 2026 [1] - The Bank will also pay a special dividend of $0.70 per share on the same date, marking the 128th consecutive quarterly dividend [2] - The Bank has a history of declaring special cash dividends, typically in the fourth quarter, but did not do so in 2023 or 2024 [2] - The level of special dividends is determined by the Bank's capital requirements and potential returns from other capital allocation options [2] - The Board of Directors will consider all capital allocation options, including future dividends and share repurchases, on a quarterly basis [3] - Hingham Institution for Savings, incorporated in 1834, is one of the oldest banks in America with offices in multiple locations including Boston and San Francisco [3]

Core Viewpoint - Phaos Technology Holdings has successfully closed an offering of 405,500 class A ordinary shares, raising gross proceeds of US$1.62 million, following the full exercise of the over-allotment option by Network 1 Financial Securities [1][2]. Group 1: Offering Details - The offering was conducted under the Company's registration statement on Form F-1, which became effective on November 11, 2025 [3]. - A final prospectus related to the offering was filed with the SEC on November 13, 2025, and is available on the SEC's website [3]. Group 2: Company Overview - Phaos Technology Holdings is an advanced microscopy technology company based in Singapore, focusing on delivering innovative microscopy products and software solutions powered by artificial intelligence for various sectors, including manufacturing, biomedical, and research [5].